GLP-1 and Mood/Depression: The Evidence (2026)

If you take Ozempic, Wegovy, Mounjaro, Zepbound or another GLP-1 and you've noticed your mood feels off — flatter, lower, less interested in things you used to enjoy — you're asking a fair and important question: can a GLP-1 cause depression or mood changes? This article is about mood and depression specifically, which is a different question from suicidal thoughts (we cover that signal in detail in the GLP-1 and suicidality regulatory review). The short version: in the large randomized trials and most big observational studies, GLP-1 drugs have not been shown to increase depression — and several cohorts and the pooled trial data actually point the other way, toward a small reduction in depressive symptoms (Wadden 2024 ^[1]; Tang 2025 ^[2]). But the picture is not uniform: pharmacovigilance databases collect reports of low mood and emotional changes, at least one new-user cohort found a small increase in depression diagnoses, and there are real nutritional and behavioral reasons rapid weight loss can affect how you feel (Tobaiqy 2024 ^[3]; Chang 2026 ^[4]). If you live with depression already, the takeaway is not to stop your medication on your own — it's to loop in your prescriber. And if you ever have thoughts of harming yourself, call or text 988 (the U.S. Suicide and Crisis Lifeline) right now.

The honest summary

• Randomized trials are reassuring on depression. A pooled analysis of the STEP 1, 2, 3 and 5 trials (more than 3,500 adults without major psychiatric illness) found semaglutide 2.4 mg did not increase depressive symptoms versus placebo; if anything, people on semaglutide were modestly less likely to worsen on the PHQ-9 depression scale (odds ratio 0.63) (Wadden 2024^[1]).
• Several large cohorts point to lower, not higher, depression risk. A target-trial-emulation study in older adults with type 2 diabetes found GLP-1 use associated with a lower risk of new depression than other glucose-lowering drugs (Tang 2025^[2]); a real-world obesity cohort found lower rates of depression, anxiety and suicidal behavior (Kornelius 2024^[5]).
• But the evidence is not unanimous. One new-user, active-comparator cohort found GLP-1 starters had a small increase in depression diagnoses versus SGLT2-inhibitor starters, and spontaneous-report databases (EudraVigilance, FAERS, VigiBase) do collect reports of depression and low mood (Chang 2026^[4]; Tobaiqy 2024^[3]; Wang 2025^[6]).
• There are plausible non-drug mechanisms for feeling flat. Eating much less, losing weight fast, and a dampened food-reward response can all blunt mood, energy and enjoyment for some people — which is a different thing from a drug directly causing clinical depression. We cover the “emotional blunting” experience separately in GLP-1s, anhedonia and emotional blunting.
• GLP-1s are being actively studied FOR depression, not just for safety. Because of the brain's reward and metabolic links, researchers are testing GLP-1 drugs as add-on treatments for depressive symptoms and mood disorders — with mixed, early results (Meshkat 2025^[7]; Li 2025^[8]; Mansur 2017^[9]).
• If you have depression, don't go it alone. Pre-existing depression is not an automatic reason to avoid a GLP-1, but it is a reason to be monitored. Don't stop antidepressants or the GLP-1 without talking to your prescriber. If you have thoughts of self-harm, call or text 988.

First, separate two different questions

“Does a GLP-1 cause depression?” and “Does a GLP-1 cause suicidal thoughts?” sound like the same question, but the evidence treats them separately and so should you. Suicidality is a discrete safety signal that regulators (the FDA and the European Medicines Agency) formally reviewed after spontaneous reports — and which large cohorts and the trial data have not confirmed; we walk through that review in the suicidality article. This page is about the broader, fuzzier experience of mood: low mood, loss of interest or pleasure (anhedonia), emotional flatness, irritability, and clinically diagnosed depression. These overlap, but a person can feel their mood has dipped without being suicidal, and the data on each are distinct.

What the randomized trials actually measured

The strongest evidence comes from the STEP program — the phase 3 trials that won semaglutide (Wegovy) its obesity approval. A 2024 post-hoc analysis pooled STEP 1, 2, 3 and 5 (more than 3,500 adults without known major psychiatric illness) and tracked depression with the validated PHQ-9 questionnaire and suicidal ideation with the Columbia rating scale (Wadden 2024^[1]). The results were reassuring: mean PHQ-9 scores stayed in the “no/minimal symptoms” range throughout (around 2 out of 27 in both groups), and at 68 weeks the placebo group's average had drifted slightly higher than the semaglutide group's (2.4 vs 2.0). Crucially, people on semaglutide were less likely to shift into a more severe depression category than people on placebo — an odds ratio of 0.63. One percent or fewer in either group reported any suicidal ideation, with no meaningful difference between drug and placebo.

What the observational evidence shows — and where it disagrees

Observational studies follow people taking the drug in the real world, including those the trials excluded. Most of the large ones lean reassuring. A target-trial-emulation study of older adults with type 2 diabetes, published in Annals of Internal Medicine, found that starting a GLP-1 was associated with a lower risk of new depression compared with starting other glucose-lowering drugs (Tang 2025^[2]). A real-world cohort of patients with obesity similarly reported lower rates of depression, anxiety and suicidal behavior on GLP-1 therapy (Kornelius 2024^[5]). And the much-publicized suicidal-ideation cohort that helped calm the original safety scare also found semaglutide users had a lower risk of incident suicidal ideation than users of other anti-obesity drugs (covered in the depression-and-suicidality evidence article).

The evidence is not unanimous, though, and honesty requires saying so. A 2026 new-user, active-comparator cohort in Diabetes, Obesity and Metabolism compared GLP-1 starters with SGLT2-inhibitor starters among overweight or obese adults with type 2 diabetes and found a small increase in depression diagnoses among the GLP-1 group (Chang 2026^[4]). Spontaneous-reporting databases — where clinicians and patients voluntarily file reports of suspected side effects — also contain depression and low-mood reports: a EudraVigilance analysis catalogued psychiatric adverse-event reports for semaglutide, liraglutide and tirzepatide (Tobaiqy 2024^[3]), and a FAERS/VigiBase pharmacovigilance study detected a statistical signal for depressive disorders (Wang 2025^[6]).

The non-drug reasons your mood might dip

Even if a GLP-1 doesn't directly cause clinical depression, several things that come with taking one can genuinely affect how you feel — and untangling them matters, because the fix is different for each.

• Eating much less. GLP-1s work by suppressing appetite. If your intake drops sharply, you can end up under-eating, low on key nutrients, and chronically low on energy — all of which can mimic or worsen low mood. Persistent fatigue and feeling “flat” sometimes track with simply not eating enough; see common GLP-1 side-effect questions.
• Rapid weight loss itself. Fast weight loss is metabolically and psychologically demanding. Some people feel euphoric; others feel destabilized, especially if food and eating were a major source of comfort or social connection.
• A dampened reward response. Part of how GLP-1s curb cravings is by quieting the brain's food-reward circuitry. For some people that quieting can feel like a broader loss of enjoyment or motivation — the “emotional blunting” some users describe (covered in anhedonia and emotional blunting on GLP-1s). Whether this is a true pharmacologic effect or a byproduct of eating and weight changes is still being worked out.
• Losing a coping mechanism. If eating was how you managed stress, removing that without a replacement can leave a gap that feels like low mood.
• GI side effects and poor sleep. Ongoing nausea, reflux or disrupted sleep wear anyone down. Feeling miserable because you feel physically unwell is real, and it's often fixable by adjusting dose or pace.

If you already have depression

Pre-existing depression is not an automatic reason to avoid a GLP-1 — many people with depression take them safely, and obesity and depression frequently travel together. But it is a clear reason to be monitored rather than left to figure it out alone. A few practical principles:

• Tell your prescriber up front. Mention any history of depression, anxiety, bipolar disorder, or self-harm before starting, and which medications you take. People with active major psychiatric illness were largely excluded from the reassuring trials, so they warrant closer follow-up (Wadden 2024^[1]).
• Don't stop your antidepressant on your own. Stopping an SSRI or other antidepressant abruptly can cause its own withdrawal and relapse problems. Coordinate any changes. (For how the two interact with weight, see GLP-1s and antidepressant interactions.)
• Watch for warning signs and name them. New or worsening low mood, loss of interest, hopelessness, sleep or appetite changes beyond what you'd expect, or any thoughts of self-harm are all reasons to contact your prescriber promptly — not to tough out.
• Make sure you're actually eating enough. Because under-eating can masquerade as depression, a low mood that coincides with very low intake is worth flagging; sometimes the answer is nutritional, not psychiatric.
• If you have thoughts of harming yourself, get help immediately. In the U.S., call or text 988 (Suicide and Crisis Lifeline) or go to an emergency room. This is urgent and not something to wait on.

Wait — GLP-1s are being studied AS a depression treatment?

Yes, and it's one of the more interesting wrinkles. The same brain pathways that make GLP-1 drugs affect appetite and reward also overlap with the circuitry involved in mood, motivation and inflammation — which has led researchers to test whether GLP-1 agonists might help depressive symptoms. Early work includes a study showing a GLP-1 agonist promoted weight-loss-linked changes in frontal-striatal brain structures in people with mood disorders (Mansur 2017^[9]). Systematic reviews have since pulled together the preclinical, observational and small clinical trials: results are mixed and preliminary — some signals of benefit on depressive and cognitive symptoms, but not enough high-quality randomized data to call GLP-1s an established depression treatment (Meshkat 2025^[7]; Li 2025^[8]).

The honest framing: the fact that researchers are studying GLP-1s for depression is reassuring context — it's hard to square “these drugs reliably cause depression” with “these drugs are being tested as antidepressant add-ons.” But “being studied as a treatment” is not the same as “proven to treat,” and none of this changes the core advice: monitor your mood, and don't self-prescribe or self-discontinue based on a headline.

Bottom line

On the central question — can a GLP-1 cause depression? — the best evidence is reassuring. The randomized STEP trials found no increase in depressive symptoms and a small reduction relative to placebo (Wadden 2024^[1]), and several large cohorts point toward lower depression risk on GLP-1 therapy (Tang 2025^[2]; Kornelius 2024^[5]). At the same time, the evidence isn't unanimous: one new-user cohort found a small increase in depression diagnoses, and spontaneous-report systems do collect low-mood reports that warrant ongoing monitoring (Chang 2026^[4]; Tobaiqy 2024^[3]; Wang 2025^[6]). Much of what people experience as “feeling off” may stem from under-eating, rapid weight loss, or a dampened reward response rather than the drug directly causing clinical depression. If you have a history of depression, that's a reason for monitoring, not avoidance — keep your prescriber in the loop, don't stop medications on your own, and if you ever have thoughts of harming yourself, call or text 988 immediately.

This article is educational and is not medical advice. Every claim above is sourced to a peer-reviewed trial analysis, cohort study, pharmacovigilance analysis, or systematic review indexed in PubMed and verified against the live PubMed database before publication. Mood and depression decisions while on a GLP-1 should be made with your prescriber and, where relevant, a mental-health professional. If you are in crisis in the U.S., call or text 988.